Etoposide Fresenius Kabi 20 mg/ml inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

etoposide fresenius kabi 20 mg/ml inf. sol. (conc.) i.v. vial

fresenius kabi sa-nv - etoposide 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - etoposide 20 mg/ml - etoposide

Etopophos New Zealand - English - Medsafe (Medicines Safety Authority)

etopophos

bristol-myers squibb (nz) limited - etoposide phosphate 1159mg equivalent to 1000 mg etoposide (includes 2% overage);   - powder for injection - 1000 mg - active: etoposide phosphate 1159mg equivalent to 1000 mg etoposide (includes 2% overage)   excipient: dextran 40 nitrogen sodium citrate dihydrate

Pfizer (Australia) ETOPOSIDE 100mg/5mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (australia) etoposide 100mg/5ml injection vial

pfizer australia pty ltd - etoposide, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute; macrogol 300; citric acid - indications as at 3 april 1996: etoposide injection is indicated for the following: small cell carcinoma of the lung. acute monocytic and myelomonocytic leukaemia. hodgkin's disease. non-hodgkin's lymphoma

ETOPOSIDE INJECTION 100 mg5 ml Singapore - English - HSA (Health Sciences Authority)

etoposide injection 100 mg5 ml

pfizer private limited - etoposide - injection - 100 mg/5 ml - etoposide 100 mg/5 ml

VEPESID Etoposide 50mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

vepesid etoposide 50mg capsule blister pack

link medical products pty ltd t/a link pharmaceuticals - etoposide, quantity: 50 mg - capsule - excipient ingredients: sodium propyl hydroxybenzoate; glycerol; sodium ethyl hydroxybenzoate; citric acid; iron oxide red; gelatin; titanium dioxide; macrogol 400; purified water - 1 - small cell carcinoma of the lung 2 - acute monocytic and myelomonocytic leukaemia 3 - hodgkins disease 4 - non-hodgkins lymphonia indications as at 5 october 2000: in the treatment of: 1. small cell carcinoma of the lung. 2. acute monocytic and myelomonocytic leukaemia. 3. hodgkin's disease. 4. non-hodgkin's lymphoma.

DBL® Etoposide New Zealand - English - Medsafe (Medicines Safety Authority)

dbl® etoposide

pfizer new zealand limited - etoposide 20 mg/ml;  ;   - solution for injection - 100 mg/5ml - active: etoposide 20 mg/ml     excipient: citric acid ethanol macrogol 300 polysorbate 80

Etoposide Concentrate for solution for infusion 20mg/ml Malta - English - Medicines Authority

etoposide concentrate for solution for infusion 20mg/ml

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - etoposide - concentrate for solution for infusion - etoposide 20 mg/ml - antineoplastic agents

ETOPOSIDE - LIQ IV 20MG/ML LIQUID Canada - English - Health Canada

etoposide - liq iv 20mg/ml liquid

bdh inc. - etoposide - liquid - 20mg - etoposide 20mg - antineoplastic agents

ETOPOSIDE LIQUID Canada - English - Health Canada

etoposide liquid

pharmel inc - etoposide - liquid - 20mg - etoposide 20mg - antineoplastic agents

ETOPOSIDE INJECTION, USP SOLUTION Canada - English - Health Canada

etoposide injection, usp solution

hospira healthcare ulc - etoposide - solution - 20mg - etoposide 20mg - antineoplastic agents